Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19675768 | 0.82 | NUDT1 (0.38) | RXRAGRIN1GRIN2BNUDT1PIN1 | |
| SCHEMBL31533165 | 0.81 | MEN1 (0.34) | PIN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL20101545 | 0.81 | MEN1 (0.34) | PIN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL20101541 | 0.80 | ALDH1A1 (0.42) | NUDT1PIN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL89746 | 0.79 | NUDT1 (0.36) | RXRAGRIN1GRIN2BNUDT1PIN1 | |
| SCHEMBL20101542 | 0.78 | PIN1 (0.51) | PIN1KDM4E | |
| SCHEMBL20107025 | 0.75 | PIN1 (0.33) | PIN1 | |
| SCHEMBL20101547 | 0.75 | PIN1 (0.40) | PIN1 | |
| SCHEMBL1996295 | 0.74 | ALDH1A1 (0.44) | RXRAGRIN1GRIN2BNUDT1PIN1 | |
| SCHEMBL20733627 | 0.72 | RPS6KA5 (0.36) | RXRAGRIN1GRIN2BNUDT1PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079728-B1 | N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES | AMGEN INC (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8022061-B2 | 5-(Methoxymethyl)-1-(5-methyl-4-(thiophen-2-yl)pyrimidin-2-yl)-N-(pyridin-4-ylmethyl)-1H-pyrazole-4-carboxamide; for the treatment or prevention of type 2 diabetes and type 2 diabetes-related conditions | AMGEN INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2079728-A1 | N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES | Amgen Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | AMGEN INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008045484-A1 | N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES | AMGEN INC. (US) | 2008-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | GLP1R, GPR119, NAT1 | RXRA 506/4885GRIN1 3453/4885GRIN2B 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.